Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8531009 | 0.81 | SLC9A1 (0.85) | SLC9A1 | |
| SCHEMBL34471843 | 0.79 | NNMT (0.48) | SLC9A1 | |
| SCHEMBL8580625 | 0.78 | SLC9A1 (0.45) | SLC9A1 | |
| SCHEMBL4638397 | 0.77 | NNMT (0.47) | — | |
| SCHEMBL7083041 | 0.76 | NNMT (0.50) | SLC9A1 | |
| SCHEMBL31401329 | 0.76 | ALDH1A1 (0.51) | SLC9A1 | |
| SCHEMBL10177915 | 0.76 | L3MBTL1 (0.56) | SLC9A1 | |
| SCHEMBL17689083 | 0.76 | ALDH1A1 (0.51) | SLC9A1 | |
| SCHEMBL11821417 | 0.74 | L3MBTL1 (0.46) | SLC9A1 | |
| SCHEMBL15478488 | 0.74 | RAPGEF4 (0.52) | SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019055590-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
| EP-2563787-B1 | AZAINDAZOLE AMIDE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-8871786-B2 | Azaindazole amide compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-28 | — | — | US | disclosed |
| US-20130203803-A1 | Azaindazole Amide Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-08 | — | — | US | disclosed |
| EP-2563787-A1 | AZAINDAZOLE AMIDE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | SLC9A1 586/4885 |
| US-20130203803-A1 | Azaindazole Amide Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | SLC9A1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.